Insmed Initiates Phase I Clinical Study for Novel Anti-Tumor Agent

Insmed, a biopharmaceutical company, has announced the initiation of a phase I clinical study for its novel anti-tumor agent, recombinant human Insulin-Like Growth Factor Binding Protein-3 (rhIGFBP-3). The study aims to evaluate the safety, tolerability, and pharmacokinetics of a single intravenous dose of rhIGFBP-3 in 30 patients. The primary goal is to identify the appropriate dose of rhIGFBP-3 for a planned phase II clinical trial in 2005. Insmed's research suggests that rhIGFBP-3 is an essential regulator of the IGF signaling pathway, which is implicated in tumor growth, and that it has potential benefits in treating various human cancers, including breast, prostate, colon, and lung cancers.

Key Takeaways:

• Insmed initiated a phase I clinical study for its novel anti-tumor agent, rhIGFBP-3, which will evaluate the safety, tolerability, and pharmacokinetics of a single intravenous dose in 30 patients.
• The primary goal of the study is to identify the appropriate dose of rhIGFBP-3 for a planned phase II clinical trial in 2005.
• Insmed's research indicates that rhIGFBP-3 is an essential regulator of the IGF signaling pathway, which is implicated in tumor growth.
• The study focuses on treating a number of human cancers, including breast, prostate, colon, and lung cancers.
• Insmed is a biopharmaceutical company focused on the discovery and development of drug candidates for the treatment of metabolic diseases and endocrine disorders with unmet medical needs.

Statistics:

• 30 patients will participate in the phase I clinical study.
• The study aims to evaluate the safety, tolerability, and pharmacokinetics of a single intravenous dose of rhIGFBP-3.
• The FDA's approval of growth factor inhibitors to treat cancer has validated this approach and encourages the development of other growth factor inhibiting agents, such as rhIGFBP-3.

Sources:

• Insmed, Inc.
• Health & Medicine Week
• NewsRx.com & NewsRx.net